A Study of PARG Inhibitor ETX-19477 in Patients With Advanced Solid Malignancies

This is a two-part, open-label, multicenter, dose escalation and dose expansion study designed to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PDx), and anti- tumor activity of ETX-19477, a novel reversible small molecule inhibitor of PARG.

Trial Details

NCT ID
NCT06395519
Phase
PHASE1 / PHASE2
Sponsor
858 Therapeutics, Inc.
Status
RECRUITING
Cancer Type
Ovarian Cancer
Interventions
  • ETX-19477
Locations (sample)
  • Phoenix, Arizona, United States|33.44838,-112.07404
  • New Haven, Connecticut, United States|41.30815,-72.92816
  • Jacksonville, Florida, United States|30.33218,-81.65565
  • Chicago, Illinois, United States|41.85003,-87.65005
  • Boston, Massachusetts, United States|42.35843,-71.05977

Key Eligibility Criteria

  • Males and females of age ≥ 18 years at the time of signing the informed consent document.
  • Histologically or cytologically confirmed advanced (incurable recurrent, unresectable, or metastatic) solid cancer, excluding primary central nervo…
  • Any solid tumor malignancy, excluding primary CNS tumors, with progression on or after or intolerance to most recent systemic therapy. Preferential…
  • Measurable disease per RECIST v1.1.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Ovarian Cancer Trials on Trialify →